News

Tom Ryder Joins Focused Ultrasound Foundation Board of Directors

CHARLOTTESVILLE, VA – Thomas O. Ryder, an investor, entrepreneur, and retired corporate executive, was elected to the Focused Ultrasound Foundation’s Board of Directors at their March 1 meeting.

Ryder has served as Chairman and CEO of the Reader’s Digest Association and President of American Express’s Travel Related Services International, Merchant Services Worldwide, and American Express Publishing Worldwide divisions.

He has experience in the publishing industry, having worked at Time Inc., CBS, and Education Today Company, Inc. where he was co-founder and CEO.

Ryder has also served on numerous boards, including at Amazon for 20 years, during which time he was audit committee chairman and the first lead independent director.

Other previous board appointments have included Starwood Hotels, RPX Corporation, Startek Corp, American Express International Bank, and Virgin Mobile – where he was Chairman.

He is also a prolific writer on the subjects of food and wine.

“Tom brings his unsurpassed skills and experience to the Foundation’s leadership team,” said Foundation Chairman Neal F. Kassell, MD. “He will help to facilitate our efforts to overcome barriers and take advantage of opportunities to shorten the time for focused ultrasound to become a global standard of care.”

Ryder is also an essential tremor patient who underwent focused ultrasound therapy for the disorder in 2021.

“Focused ultrasound fixed a major problem I had with essential tremor and changed my life,” he explains. “I truly hope my tenure on the Foundation Board of Directors will give me the opportunity to share that miracle with others in similar need.”

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and